Dark Horse Consulting Group to participate in the 2019 Alliance for Regenerative Medicine Cell & Gene Washington Forum & Legislative Fly-In

Campbell, CA, May 21, 2019 – Dark Horse Consulting Group (DHC), the leading global consultancy practice specializing in cell and gene therapy product development, will participate in the 2019 Alliance for Regenerative Medicine (ARM) Cell & Gene Forum & Legislative Fly-In on May 21-22, 2019 in Washington, D.C.

Katy Spink, Ph.D., Managing Partner and COO, will represent DHC at this significant event.

“The ARM Annual Cell and Gene Forum and Legislative Fly-In is a critical event in our industry,” said Dr Spink. “As a proud member of ARM, we greatly welcome this opportunity to hear from policy leaders and to meet with members of Congress to advocate for policies to support the development of advanced therapies for patients in urgent need.”

Day one of the ARM meeting features key policy briefings from government leaders, including with NIH Director Dr Francis Collins, congressional staffers, and Dr Celia Witten, Deputy Director of the Center for Biologics Evaluation and Research.  On day two of the event, representatives from ARM member organizations meet with key members of Congress and Administration officials to describe the immense near-term potential of advanced therapies and the need for legislation that supports the development of life saving treatments.

About Dark Horse Consulting Group

Dark Horse Consulting Group specializes in the development of cell and gene therapy products. All of our consultants have deep cell and gene therapy industry experience, spanning diverse functions including process development, device development, manufacturing, quality, regulatory, program management, nonclinical, business development, strategy, and financing/investor relations. Many of our consultants also bring experience from adjacent more mature sectors, including traditional biologics, small molecules, medical devices, and management consulting. As a result, we deeply understand the unique challenges faced by cell and gene therapy developers and are able to apply best practices from other industries to address the needs of our clients.

About The Alliance for Regenerative Medicine (ARM)

The Alliance for Regenerative Medicine (ARM) is the preeminent international organization focused specifically on the issues facing regenerative medicine and advanced therapies. We are advocates for progress in gene therapy, cell therapy, and tissue engineering. Working with our members and policymakers, we foster investment, research & development, and successful commercialization of safe, effective, and transformational therapies for patients around the world.

Read more: https://alliancerm.org/arm-event/dcforum/

We use cookies to help give you the best experience on our website. By continuing you agree to our use of cookies.